GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Appointments will continue to be issued over the next couple of weeks and pregnant women who are 28-week-plus are also ...

A single shot during pregnancy is proving to be a powerful shield for newborns against one of the most common and dangerous viruses for infants: RSV. In a new UK study, babies whose mothers received t ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

The move targets thimerosal, a preservative that anti-vaccine activists blame for neurodevelopmental disorders, despite ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

It’s not surprising that, of all the recommendations the U.S. CDC’s vaccine advisory board made at its June meeting, the first one Health and Human Services Secretary Robert Kennedy signed off on ...